Advertisement

We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

Podcast

The Explainer: Why are there still problems accessing a drug that prevents extreme morning sickness?

Listen in to hear political correspondent Christina Finn explaining the situation with Cariban.

HYPEREMESIS GRAVIDARUM IS an illness that can have a debilitating effect on pregnant women, causing constant nausea and vomiting.

People suffering from HG have been calling for years for the drug Cariban, which tackles the symptoms, to be more easily available and affordable. The government agreed to allow access to the drug via a reimbursement scheme, so that it would not cost patients up to €3,000 to access it.

However, the scheme has been criticised for the fact that it requires pregnant women to firstly get a prescription from a consultant before they can access the drug. That move has been criticised by the Irish Pharmacy Union and by some consultants themselves.

To talk us through what hyperemesis is and its considerable impact on people, what the drug Cariban does and what the scheme involves, this week our political correspondent Christina Finn joins presenter Sinéad O’Carroll.

Listen to The Explainer


The Explainer / SoundCloud

This episode was put together by presenter Laura Byrne, producers Aoife Barry and Nicky Ryan and executive producer Sinéad O’Carroll. 

Your Voice
Readers Comments
This is YOUR comments community. Stay civil, stay constructive, stay on topic. Please familiarise yourself with our comments policy here before taking part.
Leave a Comment
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.

    Leave a commentcancel